Den Europæiske Union - dansk - EMA (European Medicines Agency)

sanofi b.v. - eliglustat - gaucher sygdom - andre alimentary tract and metabolism produkter, - cerdelga er indiceret til langsigtet behandling af voksne patienter med gaucher sygdom type 1 (gd1), der er cyp2d6 fattige metabolisers (pms), mellemliggende metabolisers (ims) eller omfattende metabolisers (ems).

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

orpha devel handels- und vertr. - midazolam - filmovertrukne tabletter - 15 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

fresenius kabi ab - alanin, arginin, asparaginsyre, glutaminsyre, glycyl-l-glutamin hydrate, glycyltyrosindihydrat, histidin, isoleucin, leucin, lysinacetat, methionin, phenylalanin, prolin, serin, threonin, tryptophan, valin - infusionsvæske, opløsning

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

ethypharm - suxamethoniumchlorid (vandfrit) - injektions-/infusionsvæske, opløsning - 50 mg/ml

Den Europæiske Union - dansk - EMA (European Medicines Agency)

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabetes mellitus, type 2 - narkotika anvendt i diabetes - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. - , trepersoners-kombinationsbehandling) som supplement til diæt og motion hos patienter, der ikke er tilstrækkeligt kontrolleret på deres maksimal tolereret dosis af metformin og et sulphonylurea. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - diabetes mellitus, type 2 - narkotika anvendt i diabetes - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. it is indicated in combination with a sulphonylurea (i. - , trepersoners-kombinationsbehandling) som supplement til diæt og motion hos patienter, der ikke er tilstrækkeligt kontrolleret på deres maksimal tolereret dosis af metformin og et sulphonylurea. it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. it is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

b. braun melsungen ag - alanin, arginin, asparaginsyre, calciumchloriddihydrat, glucosemonohydrat, glutaminsyre, glycin, histidinhydrochloridmonohydrat, isoleucin, kaliumacetat, leucin, lysinhydrochlorid, magnesiumacetattetrahydrat, methionin, natriumacetattrihydrat, natriumchlorid, natriumdihydrogenphosphat dihydrat, natriumhydroxid, omega-3-syretriglycerider, phenylalanin, prolin, serin, soyaolie, threonin, triglycerider, middelkædelængde, tryptophan, valin, zinkacetatdihydrat - infusionsvæske, emulsion

Den Europæiske Union - dansk - EMA (European Medicines Agency)

covis pharma europe b.v. - formoterol fumarate dihydrate, aclidinium bromide - pulmonal sygdom, kronisk obstruktiv - medicin for obstruktiv sygdomme, - brimica genuair er indiceret som vedligeholdelsesbronkodilatorbehandling for luftstrømningsobstruktion og lindring af symptomer hos voksne patienter med kronisk obstruktiv lungesygdom (copd).

Den Europæiske Union - dansk - EMA (European Medicines Agency)

janssen-cilag international nv - bosentan (as monohydrate) - hypertension, pulmonary; scleroderma, systemic - andre antihypertensiva - behandling af pulmonal arteriel hypertension (pah) for at forbedre træningskapacitet og symptomer hos patienter med who-funktionsklasse iii. effekten har været vist i:primær (idiopatisk og familiær) pah;pah er sekundære i forhold til sklerodermi uden væsentlig interstitiel lungesygdom;pah associeret med medfødte systemisk-til-pulmonal shunt og eisenmenger ' s fysiologi. nogle forbedringer har også været vist i patienter med pah, der funktionelle klasse ii. stayveer er også angivet til at reducere antallet af nye digitale mavesår hos patienter med systemisk sklerose og løbende digital-ulcus sygdom.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

teva b.v. - betamethasondinatriumphosphat, calcipotriol hydrate - salve - 50 mikrog/g+0,5 mg/g